Suchergebnisse - "Ferro, Antonella"

PubPharm (10)

1

Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer : Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study

enthalten in: Targeted oncology | 2022

von De Laurentiis, M. | Caputo, R. | Mazza, M. | +18

2

Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy : Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Guarneri, V. | Giorgi, C. | Cinieri, S. | +23

3

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

enthalten in: BMC medicine | 2019

von Dieci, M. | Bisagni, G. | Brandes, A. | +29

4

Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials

enthalten in: Gynecologic oncology | 2019

von Daniele, G. | Arenare, L. | Scambia, G. | +25

5

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3) : a randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2018

von De Placido, S. | Gallo, C. | De Laurentiis, M. | +128

CommentIn: Lancet Oncol. 2018 Apr;19(4):431-432. - PMID 29482984

6

Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer : predictive value of DNA-PK and phosphorylated ACC

enthalten in: Oncotarget | 2016

von Perrone, F. | Baldassarre, G. | Indraccolo, S. | +27

7

Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy : a sub-study from the NeoALTTO phase III trial

enthalten in: Breast (Edinburgh, Scotland) | 2013

von Azim, H. | Rothé, F. | Aura, C. | +18

8

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO) : a randomised, open-label, multicentre, phase 3 trial

enthalten in: Lancet (London, England) | 2012

von Baselga, J. | Bradbury, I. | Eidtmann, H. | +105

ErratumIn: Lancet. 2012 Feb 18;379(9816):616 Dosage error in published abstract; MEDLINE/PubMed abstract corrected

9

Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer : the MITO-2 randomized phase III trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2011

von Pignata, S. | Scambia, G. | Ferrandina, G. | +27

10

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer : preliminary results of the MITO-2 randomized trial

enthalten in: BMC cancer | 2006

von Pignata, S. | Scambia, G. | Savarese, A. | +18

1
[1]